Stanger O - Search Results

1

Physiology of folic acid in health and disease.

Stanger O. Stanger O. Curr Drug Metab. 2002 Apr;3(2):211-23. doi: 10.2174/1389200024605163. Curr Drug Metab. 2002. PMID: 12003352 Review.

2

Clinical use and rational management of homocysteine, folic acid, and B vitamins in cardiovascular and thrombotic diseases.

Stanger O, Herrmann W, Pietrzik K, Fowler B, Geisel J, Dierkes J, Weger M. Stanger O, et al. Z Kardiol. 2004 Jun;93(6):439-53. doi: 10.1007/s00392-004-0075-3. Z Kardiol. 2004. PMID: 15252738 Review.

3

Enzymatic and non-enzymatic antioxidative effects of folic acid and its reduced derivates.

Stanger O, Wonisch W. Stanger O, et al. Subcell Biochem. 2012;56:131-61. doi: 10.1007/978-94-007-2199-9_8. Subcell Biochem. 2012. PMID: 22116698 Review.

4

Asymmetric dimethyl-L-arginine (ADMA): a possible link between homocyst(e)ine and endothelial dysfunction.

Stühlinger MC, Stanger O. Stühlinger MC, et al. Among authors: stanger o. Curr Drug Metab. 2005 Feb;6(1):3-14. doi: 10.2174/1389200052997393. Curr Drug Metab. 2005. PMID: 15720202 Review.

5

Interactions of homocysteine, nitric oxide, folate and radicals in the progressively damaged endothelium.

Stanger O, Weger M. Stanger O, et al. Clin Chem Lab Med. 2003 Nov;41(11):1444-54. doi: 10.1515/CCLM.2003.222. Clin Chem Lab Med. 2003. PMID: 14656024 Review.

6

DACH-LIGA homocystein (german, austrian and swiss homocysteine society): consensus paper on the rational clinical use of homocysteine, folic acid and B-vitamins in cardiovascular and thrombotic diseases: guidelines and recommendations.

Stanger O, Herrmann W, Pietrzik K, Fowler B, Geisel J, Dierkes J, Weger M; DACH-LIGA Homocystein e.V. Stanger O, et al. Clin Chem Lab Med. 2003 Nov;41(11):1392-403. doi: 10.1515/CCLM.2003.214. Clin Chem Lab Med. 2003. PMID: 14656016 Review.

7

Effects of folate treatment and homocysteine lowering on resistance vessel reactivity in atherosclerotic subjects.

Stanger O, Semmelrock HJ, Wonisch W, Bös U, Pabst E, Wascher TC. Stanger O, et al. J Pharmacol Exp Ther. 2002 Oct;303(1):158-62. doi: 10.1124/jpet.102.036715. J Pharmacol Exp Ther. 2002. PMID: 12235246 Clinical Trial.

8

Hyperhomocyst(e)inemia and MTHFR C677T genotypes in patients with central retinal vein occlusion.

Weger M, Stanger O, Deutschmann H, Temmel W, Renner W, Schmut O, Semmelrock J, Haas A. Weger M, et al. Among authors: stanger o. Graefes Arch Clin Exp Ophthalmol. 2002 Apr;240(4):286-90. doi: 10.1007/s00417-002-0431-9. Epub 2002 Feb 21. Graefes Arch Clin Exp Ophthalmol. 2002. PMID: 11981642

9

Homocysteine, folate and vitamin B12 in neuropsychiatric diseases: review and treatment recommendations.

Stanger O, Fowler B, Piertzik K, Huemer M, Haschke-Becher E, Semmler A, Lorenzl S, Linnebank M. Stanger O, et al. Expert Rev Neurother. 2009 Sep;9(9):1393-412. doi: 10.1586/ern.09.75. Expert Rev Neurother. 2009. PMID: 19769453 Free article. Review.

10

Hyperhomocyst(e)inaemia, but not MTHFR C677T mutation, as a risk factor for non-arteritic ischaemic optic neuropathy.

Weger M, Stanger O, Deutschmann H, Simon M, Renner W, Schmut O, Semmelrock J, Haas A. Weger M, et al. Among authors: stanger o. Br J Ophthalmol. 2001 Jul;85(7):803-6. doi: 10.1136/bjo.85.7.803. Br J Ophthalmol. 2001. PMID: 11423453 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

67 results

Search Page